MX2015000076A - Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario. - Google Patents

Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario.

Info

Publication number
MX2015000076A
MX2015000076A MX2015000076A MX2015000076A MX2015000076A MX 2015000076 A MX2015000076 A MX 2015000076A MX 2015000076 A MX2015000076 A MX 2015000076A MX 2015000076 A MX2015000076 A MX 2015000076A MX 2015000076 A MX2015000076 A MX 2015000076A
Authority
MX
Mexico
Prior art keywords
secondary hyperparathyroidism
dihydroxyvitamin
methylene
treat secondary
treat
Prior art date
Application number
MX2015000076A
Other languages
English (en)
Spanish (es)
Inventor
Hector F Deluca
Margaret Clagett-Dame
Lori A Plum
Julia B Zella
Original Assignee
Wisconsin Alumni Reasearch Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015000076(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Reasearch Foundation filed Critical Wisconsin Alumni Reasearch Foundation
Publication of MX2015000076A publication Critical patent/MX2015000076A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2015000076A 2012-06-29 2013-03-14 Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario. MX2015000076A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666264P 2012-06-29 2012-06-29
PCT/US2013/031574 WO2014003849A1 (en) 2012-06-29 2013-03-14 USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM

Publications (1)

Publication Number Publication Date
MX2015000076A true MX2015000076A (es) 2015-04-10

Family

ID=47997980

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000076A MX2015000076A (es) 2012-06-29 2013-03-14 Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario.

Country Status (19)

Country Link
US (4) US9205096B2 (OSRAM)
EP (1) EP2866811A1 (OSRAM)
JP (1) JP2015522015A (OSRAM)
KR (1) KR20150030673A (OSRAM)
CN (1) CN104394871A (OSRAM)
AU (1) AU2013281217B2 (OSRAM)
BR (1) BR112014032847A2 (OSRAM)
CA (1) CA2877680C (OSRAM)
CL (1) CL2014003565A1 (OSRAM)
CO (1) CO7240358A2 (OSRAM)
HK (1) HK1206600A1 (OSRAM)
IL (1) IL236184A0 (OSRAM)
MX (1) MX2015000076A (OSRAM)
MY (1) MY172886A (OSRAM)
NZ (1) NZ703347A (OSRAM)
RU (1) RU2666995C2 (OSRAM)
SG (1) SG11201408731WA (OSRAM)
WO (1) WO2014003849A1 (OSRAM)
ZA (1) ZA201500119B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1206600A1 (en) * 2012-06-29 2016-01-15 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM
CN105765592B (zh) 2013-09-27 2019-12-17 科德克希思公司 用于酶变体的自动筛选的方法、装置和系统
JP6309086B2 (ja) * 2013-09-27 2018-04-11 コデクシス， インコーポレイテッド 構造ベース予測モデリング
CN103533522A (zh) * 2013-10-25 2014-01-22 从兴技术有限公司 短信稽核的方法及系统
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US10369161B2 (en) * 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10105375B2 (en) 2016-08-30 2018-10-23 Wisconsin Alumni Research Foundation Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6306844B1 (en) 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US6136799A (en) 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
US6673782B2 (en) 1999-04-29 2004-01-06 Wisconsin Alumni Research Foundation Treatment of systemic lupus erythematosis
AU2001247619A1 (en) 2000-03-27 2001-10-08 Wisconsin Alumni Research Foundation Vitamin d compounds used to stabilize kidney transplants
EP1301189A2 (en) 2000-07-14 2003-04-16 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-20(S)-1$g(a),25-DIHYDROXYVITAMIN D 3? TO INCREASE BONE STRENGTH
US20080249068A1 (en) 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20060171983A1 (en) 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
KR20060040744A (ko) * 2003-09-19 2006-05-10 화이자 프로덕츠 인크. 쇠약, 근육 손상 또는 근육감소증 치료용2-알킬리덴-19-노르-비타민 ｄ 유도체
US7704980B2 (en) 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US7214671B2 (en) 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
CA2597624C (en) 2005-02-11 2012-08-14 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20s-24s)-1.alpha.,25-dihydroxyvitamin-d2
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
CA2764577C (en) * 2009-08-03 2017-12-19 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
US8604009B2 (en) 2010-03-23 2013-12-10 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3
HK1206600A1 (en) * 2012-06-29 2016-01-15 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM

Also Published As

Publication number Publication date
US9034853B2 (en) 2015-05-19
CN104394871A (zh) 2015-03-04
US9205096B2 (en) 2015-12-08
BR112014032847A2 (pt) 2017-06-27
US20140005152A1 (en) 2014-01-02
CA2877680A1 (en) 2014-01-03
CL2014003565A1 (es) 2015-08-28
MY172886A (en) 2019-12-13
US20140187522A1 (en) 2014-07-03
AU2013281217B2 (en) 2017-03-02
ZA201500119B (en) 2017-11-29
AU2013281217A1 (en) 2015-01-22
KR20150030673A (ko) 2015-03-20
IL236184A0 (en) 2015-01-29
RU2015102831A (ru) 2016-08-20
CA2877680C (en) 2017-08-29
US9717744B2 (en) 2017-08-01
EP2866811A1 (en) 2015-05-06
SG11201408731WA (en) 2015-01-29
JP2015522015A (ja) 2015-08-03
US20170252360A1 (en) 2017-09-07
US10046000B2 (en) 2018-08-14
CO7240358A2 (es) 2015-04-17
NZ703347A (en) 2016-05-27
US20160136184A1 (en) 2016-05-19
WO2014003849A1 (en) 2014-01-03
HK1206600A1 (en) 2016-01-15
RU2666995C2 (ru) 2018-09-13

Similar Documents

Publication Publication Date Title
MX2015000076A (es) Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario.
MX2016006103A (es) Suplemento a base de teacrina y metodo de uso del mismo.
CR20140376A (es) Compuestos para tratar la atrofia muscular espinal
PH12015500525A1 (en) Formulations of enzalutamide
SG11201404704UA (en) Database system using batch-oriented computation
CA143935S (en) Reformer exercise apparatus
UY34984A (es) Métodos para tratar o prevenir asma administrando un antagonista de il-4r.
PH12016501965A1 (en) S1p modulator immediate release dosage regimen
MX2015014344A (es) Terapia contra el cancer.
BR112013008492A2 (pt) recipiente de revelador, dispositivo de revelação, cartucho de processo, dispositivo de formação de imagem, e método de reabastecimento de revelador
BR112013011259A2 (pt) condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3
GT201400223A (es) Sistemas y métodos para tratar una respuesta farmacodinámica adversa inducida por opioides
IN2015DN01524A (OSRAM)
AR089320A1 (es) Cepa de lactobacillus mucosae
MX354598B (es) Uso de neuregulina para tratar lesion de nervio periferico.
CL2016001428A1 (es) Uso de una composicion con ejercicios cognitivos util para la prevencion o el tratamiento de un desarrollo cognitivo retrasado en los niños.
BR112014009760A8 (pt) análogos de ácido siálico
TW201613610A (en) Use of ginsenoside M1 for treating lupus nephritis
CL2017002304A1 (es) Métodos para tratar enfermedades
IN2015DN04070A (OSRAM)
MX2015008454A (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
BR112012024704A8 (pt) uso terapêutico de tetratiomolibdato.
IN2014KN01772A (OSRAM)
EP3240549A4 (en) Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism